BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zotemtegrast readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zotemtegrast\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07186101-21@assetmemo.bio
DTSTAMP:20261121T004510Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Zotemtegrast: Phase 2 readout est. (NCT07186101)
DESCRIPTION:Zotemtegrast\, phase 2\, Ulcerative Colitis.\nStudy: LY4268989 
 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to S
 everely Active Ulcerative Colitis:\nEstimated primary completion: May 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zotemtegrast#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07186101
URL:https://assetmemo.bio/drug/zotemtegrast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06226883-21@assetmemo.bio
DTSTAMP:20261121T004510Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zotemtegrast: Phase 2 readout est. (NCT06226883)
DESCRIPTION:Zotemtegrast\, phase 2\, Crohn's Disease.\nStudy: A Phase 2 Stu
 dy to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn
 's Disease\nEstimated primary completion: September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/zotemtegrast#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06226883
URL:https://assetmemo.bio/drug/zotemtegrast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415044-21@assetmemo.bio
DTSTAMP:20261121T004510Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Zotemtegrast: Phase 2 readout est. (NCT07415044)
DESCRIPTION:Zotemtegrast\, phase 2\, Ulcerative Colitis.\nStudy: LY4268989 
 in Adults With Moderately to Severely Active Ulcerative Colitis\nEstimated
  primary completion: June 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/zotemtegrast#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07415044
URL:https://assetmemo.bio/drug/zotemtegrast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
